Trial Profile
A Phase 2 Randomized Double-Blinded Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in Subjects With Indolent Systemic Mastocytosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary)
- Indications Systemic mastocytosis
- Focus Adverse reactions; Therapeutic Use
- 25 Aug 2023 Status changed from recruiting to completed.
- 25 Jul 2019 Planned End Date changed from 1 Jul 2027 to 1 Aug 2024.
- 20 Jun 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 3 Jun 2019 to 26 Jun 2019.